Related Experiment Video
Updated: Oct 2, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Diaphanous related formin 3 knockdown suppresses cell proliferation and metastasis of osteosarcoma cells
Zehua Zhang1, Fei Dai1, Fei Luo1
1Department of Orthopaedics, First Affiliated Hospital, Army Medical University, No. 30 Gaotanyanzheng street, Chongqing, 400038, China.
Abstract:
Osteosarcoma is a malignant osteoblastic tumor that can gravely endanger the lives and health of children and adolescents. Therefore, there is an urgent need to explore new biomarkers for osteosarcoma and determine new targeted therapies to improve the efficacy of osteosarcoma treatment. Diaphanous related formin 3 (DIAPH3) promotes tumorigenesis in hepatocellular carcinoma and lung adenocarcinoma, suggesting that DIAPH3 may be a target for tumor therapy. To date, there have been no reports on the function of DIAPH3 in osteosarcoma. DIAPH3 protein expression in osteosarcoma tissues and healthy bone tissues adjacent to cancer cells was examined by immunohistochemical staining. DIAPH3 mRNA expression correlates with overall survival and reduced disease-free survival. DIAPH3 protein is upregulated in osteosarcoma tissues, and its expression is significantly associated with tumor size, tumor stage, node metastasis, and distant metastasis. Functional in vitro experiments revealed that DIAPH3 knockdown suppressed cell proliferation and suppressed cell migration and invasion of osteosarcoma cell lines MG-63 and HOS. Functional experiments demonstrated that DIAPH3 knockdown inhibited subcutaneous tumor growth and lung metastasis in vivo. In conclusion, DIAPH3 expression can predict the clinical outcome of osteosarcoma. In addition, DIAPH3 is involved in the proliferation and metastasis of osteosarcoma, and as such, DIAPH3 may be a potential therapeutic target for osteosarcoma.
Insights
Diaphanous related formin 3 (DIAPH3) is upregulated in osteosarcoma, promoting tumor growth and metastasis. Targeting DIAPH3 may offer a new therapeutic strategy for osteosarcoma patients.
Area of Science:
- Oncology
- Molecular Biology
Background:
- Osteosarcoma is a life-threatening bone cancer in children and adolescents.
- There is a critical need for novel biomarkers and targeted therapies for osteosarcoma.
- Diaphanous related formin 3 (DIAPH3) is implicated in other cancers, but its role in osteosarcoma is unknown.
Purpose of the Study:
- To investigate the role and potential therapeutic significance of DIAPH3 in osteosarcoma.
Main Methods:
- Immunohistochemical staining to assess DIAPH3 protein expression in osteosarcoma tissues.
- Analysis of DIAPH3 mRNA expression correlation with patient survival outcomes.
- In vitro knockdown experiments in osteosarcoma cell lines (MG-63, HOS) to evaluate proliferation, migration, and invasion.
- In vivo studies using xenograft models to assess tumor growth and metastasis.
Main Results:
- DIAPH3 protein is upregulated in osteosarcoma tissues.
- Higher DIAPH3 expression correlates with advanced tumor stage, metastasis, and poorer survival.
- DIAPH3 knockdown inhibited osteosarcoma cell proliferation, migration, and invasion in vitro.
- DIAPH3 knockdown suppressed tumor growth and lung metastasis in vivo.
Conclusions:
- DIAPH3 expression serves as a predictive biomarker for osteosarcoma clinical outcomes.
- DIAPH3 plays a significant role in osteosarcoma proliferation and metastasis.
- DIAPH3 represents a potential therapeutic target for osteosarcoma treatment.

